Progression free survival with a median follow-up of 14.4 months is 96%
what is the name for that...oh yeah OVERWHELMING EFFICACY ....HMMMMMMMM maybe an IDEAL test case for the NEW authority FDA has under the NEW PDUFA act?hmmmmmmmmmmmmmm
Enjoy your quiet time here posters.......soon this will be a BOILING place filled with madness...10K posts and 1000 posters
Pharmacyclics (PCYC) is a stock creating 52-week highs on a daily basis, thanks to its one-month return of 57%. The $3.5 billion company has been on a tear in 2012, with a YTD gain of 250%. The company's pipeline of small-molecule drugs are creating quite a buzz, and thanks to heavy insider buying the stock has performed nicely for anyone who has ever purchased shares in this company.
Market Data 
Markets 
AI
